The prevalence of sleep disorders, like sleep apnea, is on the rise in the U.S., but current protocols to conduct clinically accepted assessments are expensive and inconvenient. Georgia Tech ...
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results